Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of REGN14284 in Healthy Volunteers
NCT05505448Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REGN14284 in coronavirus disease 2019 (COVID-19) (8 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at Day 169 and Serious Adverse Events at Day 169. Started Sep 2022; status: completed.
02
Drugs
REGN14284
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05505448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05505448.